NASDAQ: RGCRegencell Bioscience Holdings Ltd Stock
$6.69-0.52 (-7.21%)
Updated Sep 6, 2024
RGC Price
$6.69
Fair Value Price
$0.08
Market Cap
$87.06M
52 Week Low
$3.03
52 Week High
$32.44
P/E
-14.87x
P/B
7.24x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$5.87M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$5M
Beta
0.58
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RGC Overview
Regencell Bioscience Holdings Limited is a bioscience company developing traditional Chinese medicines to treat neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder and autism spectrum disorder. Regencell Bioscience incorporated in 2014 and is headquartered in Hong Kong.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RGC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RGC ($6.69) is overvalued by 7,806.1% relative to our estimate of its Fair Value price of $0.08 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RGC ($6.69) is not significantly undervalued (7,806.1%) relative to our estimate of its Fair Value price of $0.08 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RGC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RGC due diligence checks available for Premium users.
Be the first to know about important RGC news, forecast changes, insider trades & much more!
RGC News
Valuation
RGC fair value
Fair Value of RGC stock based on Discounted Cash Flow (DCF)
Price
$6.69
Fair Value
$0.08
Overvalued by
7,806.10%
RGC ($6.69) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RGC ($6.69) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RGC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RGC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-14.87x
Industry
20.61x
Market
24.57x
RGC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.24x
Industry
2.28x
RGC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RGC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
RGC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.6M
Liabilities
$632.3k
Debt to equity
0.05
RGC's short-term assets ($11.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RGC's short-term assets ($11.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RGC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
RGC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RGC vs Pharmaceutical Stocks
Regencell Bioscience Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.